Samsung Biologics Co.,Ltd. (207940.KS)

KRW 959000.0

(-2.14%)

Operating Income Summary of Samsung Biologics Co.,Ltd.

Samsung Biologics Co.,Ltd.'s latest annual operating income in 2023 was 1155.98 Billion KRW , up 13.22% from previous year.
Samsung Biologics Co.,Ltd.'s latest quarterly operating income in 2024 Q3 was 338.57 Billion KRW , down -22.08% from previous quarter.
Samsung Biologics Co.,Ltd. reported an annual operating income of 983.62 Billion KRW in 2022, up 83.07% from previous year.
Samsung Biologics Co.,Ltd. reported an annual operating income of 537.3 Billion KRW in 2021, up 83.52% from previous year.
Samsung Biologics Co.,Ltd. reported a quarterly operating income of 338.57 Billion KRW for 2024 Q3, down -22.08% from previous quarter.
Samsung Biologics Co.,Ltd. reported a quarterly operating income of 221.29 Billion KRW for 2024 Q1, down -36.77% from previous quarter.

Annual Operating Income Chart of Samsung Biologics Co.,Ltd. (2023 - 2014)

Historical Annual Operating Income of Samsung Biologics Co.,Ltd. (2023 - 2014)

Year	Operating Income	Operating Income Growth
2023	1155.98 Billion KRW	13.22%
2022	983.62 Billion KRW	83.07%
2021	537.3 Billion KRW	83.52%
2020	292.78 Billion KRW	62.1%
2019	180.61 Billion KRW	224.39%
2018	55.67 Billion KRW	-15.61%
2017	65.97 Billion KRW	316.88%
2016	-30.42 Billion KRW	85.06%
2015	-203.64 Billion KRW	-70.35%
2014	-119.54 Billion KRW	0.0%

Year	Operating Income	Operating Income Growth
2024 Q2	434.51 Billion KRW	96.35%
2024 Q3	338.57 Billion KRW	-22.08%
2024 Q1	221.29 Billion KRW	-36.77%
2023 Q1	191.74 Billion KRW	-55.63%
2023 Q3	318.53 Billion KRW	25.68%
2023 Q2	253.43 Billion KRW	32.18%
2023 Q4	349.96 Billion KRW	9.87%
2023 FY	1113.68 Billion KRW	13.22%
2022 Q2	169.67 Billion KRW	-3.82%
2022 FY	983.62 Billion KRW	83.07%
2022 Q4	432.17 Billion KRW	105.05%
2022 Q3	210.76 Billion KRW	24.22%
2022 Q1	176.41 Billion KRW	36.92%
2021 Q2	166.76 Billion KRW	124.45%
2021 FY	537.3 Billion KRW	83.52%
2021 Q4	128.84 Billion KRW	-23.04%
2021 Q3	167.41 Billion KRW	0.39%
2021 Q1	74.29 Billion KRW	-19.75%
2020 Q4	92.57 Billion KRW	63.75%
2020 Q3	56.53 Billion KRW	-30.29%
2020 Q1	62.57 Billion KRW	-41.5%
2020 FY	292.78 Billion KRW	62.1%
2020 Q2	81.1 Billion KRW	29.61%
2019 Q1	-23.39 Billion KRW	-303.43%
2019 FY	180.61 Billion KRW	224.39%
2019 Q4	106.95 Billion KRW	353.04%
2019 Q3	23.6 Billion KRW	253.0%
2019 Q2	-15.43 Billion KRW	34.04%
2018 Q2	23.71 Billion KRW	137.28%
2018 FY	55.67 Billion KRW	-15.61%
2018 Q4	11.5 Billion KRW	9.89%
2018 Q3	10.46 Billion KRW	-55.88%
2018 Q1	9.99 Billion KRW	-80.24%
2017 Q4	50.58 Billion KRW	147.2%
2017 Q1	3.4 Billion KRW	583.21%
2017 FY	65.97 Billion KRW	316.88%
2017 Q2	-8.48 Billion KRW	-348.97%
2017 Q3	20.46 Billion KRW	341.24%
2016 Q3	-12.86 Billion KRW	-303.04%
2016 Q2	-3.19 Billion KRW	76.64%
2016 Q4	-705.16 Million KRW	94.52%
2016 Q1	-13.66 Billion KRW	0.0%
2016 FY	-30.42 Billion KRW	85.06%
2015 FY	-203.64 Billion KRW	-70.35%
2014 FY	-119.54 Billion KRW	0.0%

Peer Operating Income Comparison of Samsung Biologics Co.,Ltd.

Name	Operating Income	Operating Income Difference
ORIENT BIO Inc.	1.45 Billion KRW	-79469.237%
Green Cross Holdings Corporation	-16.43 Billion KRW	7132.459%
Green Cross Holdings Corporation	34.43 Billion KRW	-3256.906%
Pharmicell Co., Ltd.	950.99 Million KRW	-121455.641%
Green Cross Corporation	34.43 Billion KRW	-3256.906%
GeneOne Life Science, Inc.	-48.36 Billion KRW	2489.987%
Celltrion, Inc.	651.43 Billion KRW	-77.453%
SK bioscience Co.,Ltd.	-4.73 Billion KRW	24534.429%
SK Biopharmaceuticals Co., Ltd.	-37.52 Billion KRW	3180.816%
Prestige BioPharma Limited	-62.78 Billion KRW	1941.249%